TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04475458

Intervention type: PROCEDURE
Intervention: Ultrasound-guided dorsal penile nerve block
Description: This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
Study: NCT02372604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.
Description: Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~* the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~* the evening : 10 mg of levocetirizine (capsule))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
Description: Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~* the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~* the evening : placebo tablet
Study: NCT01183689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Behavior Changes
Description: The Self-Regulation Plus Small Behavior Changes Intervention will focus on making small changes in diet and physical activity on a daily basis to prevent weight gain.~Diet: The dietary approach used in this group is to identify small changes in what and how much participants eat each day. The general concept is that these are small, manageable changes that will produce small reductions in overall intake and can easily be made on a daily basis and maintained over time.~Exercise: At the start of the program, participants will be given a pedometer and asked to record their current or baseline number of steps. They will then be given the goal of increasing their daily steps by 2000 steps per day over this baseline level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Large Behavior Changes
Description: The focus of this intervention group will be on periodically making large changes in diet and physical activity, with the goal of losing 5-10 pounds to buffer against the weight gain that often occurs during young adulthood.~Diet: Individuals with a BMI of 21-24.9 kg/m2 will be encouraged to lose 5 pounds; those with a BMI of 25-30 kg/m2 will be encouraged to lose 10 pounds.~Exercise: The Large Changes group will be instructed to gradually increase their minutes of physical activity until achieving 250 minutes per week (5 days/week with 50 minutes per day) using activities similar in intensity to brisk walking.
Study: NCT01414803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid modification
Description: rosuvastatin 10 mg/fenofibrate 160 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid modification
Description: rosuvastatin 10 mg per day
Study: NCT03247647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Intervention
Description: Participants will write about the food they have eaten in the last 48 hours.
Study: NCT02649582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine plus temozolomide chemotherapy
Description: When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~1. Leukocyte apheresis (before chemoradiation): for DC vaccine production~2. Chemoradiation (standard treatment: initiated as soon as the patient's hematological blood values are adequate after apheresis): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~3. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (+/-1 day) for 3 weeks, starting ≥ 1 week after radiotherapy~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 2 days (max. 12 months) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle
Study: NCT02173769

Intervention type: DRUG
Intervention: Spiriva® Respimat®
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®

Intervention type: DRUG
Intervention: Striverdi® Respimat®
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
Study: NCT01361230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedation Trial Monitor is the name of the device used.
Description: This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
Study: NCT00181168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euthyroid Group
Description: Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
Study: NCT01775501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02151864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
Study: NCT03459079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanifibranor
Description: The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
Study: NCT00631514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piroxicam
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piroxicam
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Study: NCT00879736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THT PACE Training
Description: Patient training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THT PACE Training
Description: Patient training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03016728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
Study: NCT01195766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab in addition with ESHAP therapy
Study: NCT02437045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
Study: NCT05690139

Intervention type: PROCEDURE
Intervention: Pre-operative LSG patients
Description: Baseline

Intervention type: PROCEDURE
Intervention: Post-operative patients 1st month
Description: 1 month after surgery

Intervention type: PROCEDURE
Intervention: Post-operative patients 3rd month
Description: 3 months after surgery

Intervention type: PROCEDURE
Intervention: Post-operative patients 6th month
Description: 6 months after surgery
Study: NCT04642027

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sEBRT
Description: A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated sEBRT
Description: A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
Study: NCT02759614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg, orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150mg, orally once a day
Study: NCT03938233

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system
Description: The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system
Description: The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
Study: NCT03117751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or intramuscularly (IM) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or intramuscularly (IM) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or intramuscularly (IM) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or intramuscularly (IM) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or intramuscularly (IM) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase®
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase®
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase®
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
Study: NCT02731573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open heart surgery
Description: Subject will undergo open heart surgery according to standard of care
Study: NCT00618982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
Study: NCT04340323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
Study: NCT03573726

Intervention type: OTHER
Group type: OTHER
Intervention: Closed diurnal indwelling catheter (CDIC)
Description: Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
Study: NCT01895283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training
Description: Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
Study: NCT03078426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic HRCT (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic HRCT (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic HRCT (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic HRCT (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
Study: NCT01676181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy
Description: Total removal of tonsils and adenoid tissue with cold-steel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillotomy
Description: Partial removal of tonsils with coblation and total removal of adenoids with cold steel
Study: NCT01991054

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Study: NCT01583153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Inpatient Rehabilitation
Description: Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Home Programme (HO)
Description: The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
Study: NCT02935933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivicaine
Description: Paravertebral block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivicaine
Description: Paravertebral block
Study: NCT03117751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase®
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase®
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study: NCT02935933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivicaine
Description: Paravertebral block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine